tradingkey.logo
tradingkey.logo
Search

Castle Biosciences Inc

CSTL
Add to Watchlist
18.150USD
-0.480-2.58%
Close 05/13, 16:00ETQuotes delayed by 15 min
550.49MMarket Cap
LossP/E TTM

Castle Biosciences Inc

18.150
-0.480-2.58%
View Detailed Chart
Intraday
1m
30m
1h
D
W
M
D

Today

-2.58%

5 Days

-26.67%

1 Month

-22.86%

6 Months

-46.81%

Year to Date

-53.34%

1 Year

+6.58%

Key Insights

Castle Biosciences Inc's fundamentals are relatively very healthy, with an industry-leading ESG disclosure.and its growth potential is significant.Its valuation is considered fairly valued, ranking 14 out of 206 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Strong Buy, with the highest price target at 47.12.In the medium term, the stock price is expected to trend down.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Castle Biosciences Inc's Score

Industry at a Glance

Industry Ranking
14 / 206
Overall Ranking
85 / 4487
Industry
Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score
Previous score

Media Coverage

Last 24 hours
Coverage Level

Very Low
Very High
Neutral

Castle Biosciences Inc Highlights

StrengthsRisks
Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 56.62% year-on-year.
Turnaround to Loss
The company's performance has turned to a loss, with the latest annual loss of USD .
Fairly Valued
The company’s latest PE is -43.65, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 27.62M shares, decreasing 6.13% quarter-over-quarter.
Held by Murray Stahl
Star Investor Murray Stahl holds 4.31K shares of this stock.

Analyst Rating

Based on 8 analysts
Strong Buy
Current Rating
47.125
Target Price
+147.51%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Castle Biosciences Inc News

More news coming soon, stay tuned...

Financial Indicators

EPS

Relevant data have not been disclosed by the company yet.

Total revenue

Relevant data have not been disclosed by the company yet.

Castle Biosciences Inc Info

Castle Biosciences, Inc. is a molecular diagnostics company offering test solutions to aid clinicians in the diagnosis and treatment of dermatologic cancers, Barrett’s esophagus (BE), uveal melanoma (UM), and in the treatment of mental health conditions. The Company offers five commercially available proprietary multi-analyte assays with algorithmic analysis (MAAA) tests for use in the fields of dermatology, gastroenterology and ophthalmology. It also offers a proprietary pharmacogenomic (PGx) test to guide optimal drug treatment for patients diagnosed with depression, anxiety and other mental health conditions. Its products include DecisionDx-Melanoma, DecisionDx-SCC, MyPath Melanoma, TissueCypher, IDgenetix, and DecisionDx-UM. DecisionDx-SCC is its proprietary gene expression profile (GEP) test for use in patients with cutaneous squamous cell carcinoma (SCC). It also focused on chronic acid reflux related diseases, including esophageal cancer.
Ticker SymbolCSTL
CompanyCastle Biosciences Inc
CEOMaetzold (Derek J)
Websitehttps://castlebiosciences.com/
KeyAI